Heart failure with preserved ejection fraction (HFpEF) is a complex clinical syndrome that accounts for more than half of all heart failure patients. Identification, early diagnosis and management of patients are still complex, and no targeted treatment is available, since all tested drugs were not able to lower hard clinical outcomes. A multi-hormonal deficiency syndrome has been described in HFpEF patients suggesting that different hormones may represent new biomarkers of the disease, but their clinical utility is still debated. The natriuretic peptides are the cornerstone biomarker in heart failure, predicting cardiovascular death and heart failure hospitalization. Testosterone and DHEA-S deficiencies have been reported in HFpEF and associated with right ventricular impairment and diastolic dysfunction. IGFBP-1/IGF-1 axis correlates with echocardiographic parameters of HFpEF patients and with several prognostic biomarkers including NT-proBNP and C reactive protein. Low triiodothyronine syndrome is frequently found in HFpEF and thyroid hormones should represent a potential biomarker of risk stratification and prognosis.

Anabolic hormones and heart failure with preserved ejection fraction: looking for Ariadne's thread / De Luca, Mariarosaria; Crisci, Giulia; Giardino, Federica; Valente, Valeria; Amaranto, Ilaria; Iacono, Olimpia; D'Assante, Roberta; Giallauria, Francesco; Marra, Alberto M. - In: MONALDI ARCHIVES FOR CHEST DISEASE. - ISSN 1122-0643. - (2021). [10.4081/monaldi.2021.1743]

Anabolic hormones and heart failure with preserved ejection fraction: looking for Ariadne's thread

De Luca, Mariarosaria;Crisci, Giulia;Giardino, Federica;Valente, Valeria;Amaranto, Ilaria;Iacono, Olimpia;D'Assante, Roberta;Giallauria, Francesco;Marra, Alberto M
2021

Abstract

Heart failure with preserved ejection fraction (HFpEF) is a complex clinical syndrome that accounts for more than half of all heart failure patients. Identification, early diagnosis and management of patients are still complex, and no targeted treatment is available, since all tested drugs were not able to lower hard clinical outcomes. A multi-hormonal deficiency syndrome has been described in HFpEF patients suggesting that different hormones may represent new biomarkers of the disease, but their clinical utility is still debated. The natriuretic peptides are the cornerstone biomarker in heart failure, predicting cardiovascular death and heart failure hospitalization. Testosterone and DHEA-S deficiencies have been reported in HFpEF and associated with right ventricular impairment and diastolic dysfunction. IGFBP-1/IGF-1 axis correlates with echocardiographic parameters of HFpEF patients and with several prognostic biomarkers including NT-proBNP and C reactive protein. Low triiodothyronine syndrome is frequently found in HFpEF and thyroid hormones should represent a potential biomarker of risk stratification and prognosis.
2021
Anabolic hormones and heart failure with preserved ejection fraction: looking for Ariadne's thread / De Luca, Mariarosaria; Crisci, Giulia; Giardino, Federica; Valente, Valeria; Amaranto, Ilaria; Iacono, Olimpia; D'Assante, Roberta; Giallauria, Francesco; Marra, Alberto M. - In: MONALDI ARCHIVES FOR CHEST DISEASE. - ISSN 1122-0643. - (2021). [10.4081/monaldi.2021.1743]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/858831
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 0
social impact